- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:08 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment | 326 | GlobeNewswire (Europe) | NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 17.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders | 158 | GlobeNewswire (Europe) | NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 14.02. | Psyence Biomedical Ltd.: Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway | 379 | GlobeNewswire (Europe) | NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 12.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.02. | Psyence Biomedical-Aktie fällt nach Beilegung von Aktionärsstreit | 1 | Investing.com Deutsch | ||
| 11.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Settlement of Shareholder Litigation | 193 | GlobeNewswire (Europe) | NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct... ► Artikel lesen | |
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 03.02. | Morning Market Movers: FatPipe, FiEE, Teradyne, Psyence Biomedical, See Big Swings | 425 | AFX News | OTTAWA (dpa-AFX) - At 6:44 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 29.01. | Psyence Biomedical announces 1-for-6.25 share consolidation | 2 | Investing.com | ||
| 29.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split | 86 | GlobeNewswire (Europe) | NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced the effective date of its 1-for-6.25 share consolidation (reverse... ► Artikel lesen | |
| 27.01. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 | 2 | GlobeNewswire (USA) | ||
| 20.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date | 172 | GlobeNewswire (Europe) | NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced that it has decided to postpone the previously announced effective... ► Artikel lesen | |
| 15.01. | Psyence Biomedical sets Jan. 20 as effective date for reverse stock split | 1 | Seeking Alpha | ||
| 15.01. | Psyence Biomedical announces 1-for-6.25 share consolidation | 1 | Investing.com | ||
| 15.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split | 234 | GlobeNewswire (Europe) | NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced the effective date of its 1-for-6.25 share consolidation (reverse... ► Artikel lesen | |
| 08.01. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.01. | Psyence Biomedical Ltd.: Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash | 1 | GlobeNewswire (USA) | ||
| 19.12.25 | Psyence Biomedical: Aktie steigt nach Ethik-Zustimmung für Psilocybin-Studie | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 2,160 | -1,37 % | BioLineRx Ltd. - 6-K, Report of foreign issuer | ||
| TRANSCODE THERAPEUTICS | 9,870 | 0,00 % | Transcode Therapeutics, Inc. - 8-K, Current Report | ||
| SILEXION THERAPEUTICS | 1,730 | 0,00 % | Silexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 | SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated... ► Artikel lesen | |
| MINK THERAPEUTICS | 8,350 | 0,00 % | MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 62,98 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights | Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS... ► Artikel lesen | |
| ARCELLX | 113,80 | -0,05 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| QIAGEN | 41,310 | -0,19 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| BIONTECH | 93,15 | -0,16 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,100 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| CARDIO DIAGNOSTICS | 6,490 | 0,00 % | Women in power: Scatec CDIO Kine Årdal conquers oil and gas, renewables and digitalisation | ||
| ADMA BIOLOGICS | 15,580 | 0,00 % | ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance | ||
| RELAY THERAPEUTICS | 10,250 | 0,00 % | Relay Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PRAXIS PRECISION MEDICINES | 336,75 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,820 | 0,00 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| KYMERA THERAPEUTICS | 91,36 | 0,00 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.